U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H27N3O3
Molecular Weight 381.4681
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GANSTIGMINE

SMILES

[H][C@]12ON(C)CC[C@@]1(C)C3=CC(OC(=O)NC4=CC=CC=C4CC)=CC=C3N2C

InChI

InChIKey=ZOBDWFRKFSPCRB-UNMCSNQZSA-N
InChI=1S/C22H27N3O3/c1-5-15-8-6-7-9-18(15)23-21(26)27-16-10-11-19-17(14-16)22(2)12-13-24(3)28-20(22)25(19)4/h6-11,14,20H,5,12-13H2,1-4H3,(H,23,26)/t20-,22-/m0/s1

HIDE SMILES / InChI

Molecular Formula C22H27N3O3
Molecular Weight 381.4681
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Ganstigmine is an orally active, carbamate-based acetylcholinesterase (AChE) inhibitor developed for the treatment of Alzheimer's disease. It is a newer generation AChE than BChE inhibitor, derived from genserine, and has a long duration of action in vivo. Studies have shown it significantly prevented the progressive neuronal cell death due to growth factor deprivation and decreased neurodegeneration. Ganstigmine may be a suitable candidate for the treatment of cholinergic deficit in Alzheimer's disease because it was found to significantly increase basal extracellular concentrations of acetylcholine in rat prefrontal cortex, and does not affect the concentrations of serotonin, noradrenaline and levels of dopamine and metabolites. It is safe and well tolerated at 5–10 mg doses as the study conducted in Phase I randomized, double-blind, placebo-controlled clinical trial. It was dropped from phase II trials because of its adverse effects reported in some patients.

Approval Year

Substance Class Chemical
Created
by admin
on Fri Dec 15 17:13:19 GMT 2023
Edited
by admin
on Fri Dec 15 17:13:19 GMT 2023
Record UNII
QRR9SV89XI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GANSTIGMINE
INN  
INN  
Official Name English
ganstigmine [INN]
Common Name English
(4AS,9AS)-2,3,4,4A,9,9A-HEXAHYDRO-2,4A,9-TRIMETHYL-1,2-OXAZINO(6,5-B)INDOL-6-YL O-ETHYLCARBANILATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C47792
Created by admin on Fri Dec 15 17:13:19 GMT 2023 , Edited by admin on Fri Dec 15 17:13:19 GMT 2023
Code System Code Type Description
ChEMBL
CHEMBL121810
Created by admin on Fri Dec 15 17:13:19 GMT 2023 , Edited by admin on Fri Dec 15 17:13:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID30196607
Created by admin on Fri Dec 15 17:13:19 GMT 2023 , Edited by admin on Fri Dec 15 17:13:19 GMT 2023
PRIMARY
INN
7844
Created by admin on Fri Dec 15 17:13:19 GMT 2023 , Edited by admin on Fri Dec 15 17:13:19 GMT 2023
PRIMARY
SMS_ID
300000036944
Created by admin on Fri Dec 15 17:13:19 GMT 2023 , Edited by admin on Fri Dec 15 17:13:19 GMT 2023
PRIMARY
FDA UNII
QRR9SV89XI
Created by admin on Fri Dec 15 17:13:19 GMT 2023 , Edited by admin on Fri Dec 15 17:13:19 GMT 2023
PRIMARY
PUBCHEM
9823294
Created by admin on Fri Dec 15 17:13:19 GMT 2023 , Edited by admin on Fri Dec 15 17:13:19 GMT 2023
PRIMARY
MESH
C447079
Created by admin on Fri Dec 15 17:13:19 GMT 2023 , Edited by admin on Fri Dec 15 17:13:19 GMT 2023
PRIMARY
NCI_THESAURUS
C87575
Created by admin on Fri Dec 15 17:13:19 GMT 2023 , Edited by admin on Fri Dec 15 17:13:19 GMT 2023
PRIMARY
CAS
457075-21-7
Created by admin on Fri Dec 15 17:13:19 GMT 2023 , Edited by admin on Fri Dec 15 17:13:19 GMT 2023
PRIMARY
DRUG BANK
DB06525
Created by admin on Fri Dec 15 17:13:19 GMT 2023 , Edited by admin on Fri Dec 15 17:13:19 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY